A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer.
Saved in:
| Title: | A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer. |
|---|---|
| Authors: | Bendell JC; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee, USA jbendell@tnonc.com., Hochster H; Yale School of Medicine, New Haven, Connecticut, USA., Hart LL; Sarah Cannon Research Institute/Florida Cancer Specialists, Fort Myers, Florida, USA., Firdaus I; Sarah Cannon Research Institute/Oncology Hematology Care, Cincinnati, Ohio, USA., Mace JR; Sarah Cannon Research Institute/Florida Cancer Specialists, St Petersburg, Florida, USA., McFarlane JJ; Sarah Cannon Research Institute/Virginia Cancer Institute, Richmond, Virginia, USA., Kozloff M; University of Chicago, Chicago, Illinois, USA., Catenacci D; University of Chicago, Chicago, Illinois, USA., Hsu JJ; Genentech Inc., South San Francisco, California, USA., Hack SP; Genentech Inc., South San Francisco, California, USA., Shames DS; Genentech Inc., South San Francisco, California, USA., Phan SC; Genentech Inc., South San Francisco, California, USA., Koeppen H; Genentech Inc., South San Francisco, California, USA., Cohn AL; Rocky Mountain Cancer Center, Denver, Colorado, USA. |
| Source: | The oncologist [Oncologist] 2017 Mar; Vol. 22 (3), pp. 264-271. Date of Electronic Publication: 2017 Feb 16. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 28209746 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Bendell+JC%22">Bendell JC</searchLink>; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee, USA jbendell@tnonc.com.<br /><searchLink fieldCode="AU" term="%22Hochster+H%22">Hochster H</searchLink>; Yale School of Medicine, New Haven, Connecticut, USA.<br /><searchLink fieldCode="AU" term="%22Hart+LL%22">Hart LL</searchLink>; Sarah Cannon Research Institute/Florida Cancer Specialists, Fort Myers, Florida, USA.<br /><searchLink fieldCode="AU" term="%22Firdaus+I%22">Firdaus I</searchLink>; Sarah Cannon Research Institute/Oncology Hematology Care, Cincinnati, Ohio, USA.<br /><searchLink fieldCode="AU" term="%22Mace+JR%22">Mace JR</searchLink>; Sarah Cannon Research Institute/Florida Cancer Specialists, St Petersburg, Florida, USA.<br /><searchLink fieldCode="AU" term="%22McFarlane+JJ%22">McFarlane JJ</searchLink>; Sarah Cannon Research Institute/Virginia Cancer Institute, Richmond, Virginia, USA.<br /><searchLink fieldCode="AU" term="%22Kozloff+M%22">Kozloff M</searchLink>; University of Chicago, Chicago, Illinois, USA.<br /><searchLink fieldCode="AU" term="%22Catenacci+D%22">Catenacci D</searchLink>; University of Chicago, Chicago, Illinois, USA.<br /><searchLink fieldCode="AU" term="%22Hsu+JJ%22">Hsu JJ</searchLink>; Genentech Inc., South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Hack+SP%22">Hack SP</searchLink>; Genentech Inc., South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Shames+DS%22">Shames DS</searchLink>; Genentech Inc., South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Phan+SC%22">Phan SC</searchLink>; Genentech Inc., South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Koeppen+H%22">Koeppen H</searchLink>; Genentech Inc., South San Francisco, California, USA.<br /><searchLink fieldCode="AU" term="%22Cohn+AL%22">Cohn AL</searchLink>; Rocky Mountain Cancer Center, Denver, Colorado, USA. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%229607837%22">The oncologist</searchLink> [Oncologist] 2017 Mar; Vol. 22 (3), pp. 264-271. <i>Date of Electronic Publication: </i>2017 Feb 16. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Oxford+University+Press%22">Oxford University Press </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9607837 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1549-490X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210837159%22">10837159 </searchLink><i>NLM ISO Abbreviation: </i>Oncologist <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=28209746 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1634/theoncologist.2016-0223 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 264 Titles: – TitleFull: A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Bendell JC – PersonEntity: Name: NameFull: Hochster H – PersonEntity: Name: NameFull: Hart LL – PersonEntity: Name: NameFull: Firdaus I – PersonEntity: Name: NameFull: Mace JR – PersonEntity: Name: NameFull: McFarlane JJ – PersonEntity: Name: NameFull: Kozloff M – PersonEntity: Name: NameFull: Catenacci D – PersonEntity: Name: NameFull: Hsu JJ – PersonEntity: Name: NameFull: Hack SP – PersonEntity: Name: NameFull: Shames DS – PersonEntity: Name: NameFull: Phan SC – PersonEntity: Name: NameFull: Koeppen H – PersonEntity: Name: NameFull: Cohn AL IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 03 Text: 2017 Mar Type: published Y: 2017 Identifiers: – Type: issn-electronic Value: 1549-490X Numbering: – Type: volume Value: 22 – Type: issue Value: 3 Titles: – TitleFull: The oncologist Type: main |
| ResultId | 1 |
